What is Click Therapeutics?
Click Therapeutics operates at the intersection of neuroscience and digital innovation, developing software-based prescription treatments delivered via mobile applications. By focusing on clinically validated digital therapeutics, the company provides regulated, evidence-based solutions that integrate seamlessly into existing healthcare systems. This approach not only improves patient outcomes but also expands access to care for conditions that have historically lacked effective, scalable interventions. The company's market position is defined by its commitment to rigorous clinical validation, ensuring that its digital products meet the same high standards as traditional pharmaceutical treatments.
How much funding has Click Therapeutics raised?
Click Therapeutics has raised a total of $242.5M across 13 funding rounds:
Series A
$19M
Debt
$350K
Debt
$30M
Series B
$52M
Debt
$15M
Debt
$20M
Other Financing Round
$48.5M
Series D
$50M
Series A (2018): $19M with participation from Sanofi Ventures and Hikma Ventures
Debt (2020): $350K led by PPP
Debt (2020): $30M supported by K2 HealthVentures
Series B (2021): $52M featuring Ridgetop Health, H.I.G. BioHealth Partners, REVELATION PARTNERS, Sanofi Ventures, Hikma Ventures, Accelmed, K2 HealthVentures, and Health Catalyst Capital Management
Debt (2022): $15M backed by Silicon Valley Bank
Debt (2023): $20M with participation from HSBC
Other Financing Round (2025): $48.5M, investors not publicly disclosed
Series D (2026): $50M supported by Boehringer Ingelheim
Key Investors in Click Therapeutics
Ridgetop Health
A mid to late stage private equity platform focused on life science companies, with a strong emphasis on digital health, early disease detection, and precision medicine technologies.
Sanofi Ventures
The corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies with transformative products of strategic interest to the parent organization.
Boehringer Ingelheim
A research-driven pharmaceutical company focused on developing prescription medicines and healthcare products across human pharma, animal health, and biopharmaceutical manufacturing.
What's next for Click Therapeutics?
With the recent influx of $50M, Click Therapeutics is well-positioned to accelerate its product development pipeline and expand its commercial footprint. The company's strategic focus will likely center on deepening its integration with major healthcare providers and payers, further validating the efficacy of its digital therapeutics in real-world settings. As the firm moves into its next phase of maturity, the emphasis will remain on scaling its platform to address a broader range of therapeutic areas, potentially leveraging its existing partnerships with global pharmaceutical leaders to drive adoption and long-term sustainability in the competitive HealthTech landscape.
See full Click Therapeutics company page
